FDA has approved the trade name Firmagon for degarelix for injection, a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer. “This ...
New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-term Suppression of Testosterone - a hormone that stimulates prostate cancer growth. PARSIPPANY, N.J., Dec. 24 ...
Degarelix is a new hormonal therapy from the GnRH receptor blocker class of agents that immediately blocks the GnRH receptor and achieves fast testosterone suppression without an initial surge. In the ...
ORLANDO—Prostate cancer (PCa) patients treated with degarelix have a lower risk of PSA failure or death compared with those treated with leuprolide, according to the findings of a long-term study. The ...
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hgtc2g/firmagon) has announced the addition of GlobalData's new report ...
Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...
Pooled data from five phase III studies of men with prostate cancer (n = 1,925) confirm that androgen deprivation therapy (ADT) with degarelix, a gonadotropin-releasing hormone antagonist, offers ...
Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, ...
CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results